CaRi-heart technology
Revolutionary new technology to assess the risk of a serious heart condition or heart attack – many years before anything happens.
Latest anti-cancer therapies and clinical trials
At HCA Healthcare UK the latest advancements in genomic testing, immunotherapy, targeted therapies and access to clinical trials are transforming the way we treat gynaecological cancers.
What are anti-cancer therapies?
Anti-cancer therapies are types of treatment used to treat gynaecological cancers. The main anti-cancer therapies are chemotherapy and radiotherapy, which continue to be highly effective in treating certain gynaecological cancers and, combined with surgery, are the main standard therapies. The type of anti-cancer therapy which is recommended to you will depend on your individual diagnosis, including the type and stage of gynaecological cancer you have been diagnosed with. For example, the majority of ovarian cancer treatment plans include chemotherapy and the majority of vaginal cancer treatment plans will include radiotherapy.
New technologies and treatment techniques mean that anti-cancer therapies are an ever-advancing area of medicine. Through our healthcare system our experts can provide the full range of treatment options, from standard therapies, such as chemotherapy and radiotherapy, to the latest immunotherapies, targeted and hormone therapies, as well as access to the very latest therapies at the earliest opportunity through clinical trials.
Personalised medicine through genomic testing
What is genomic testing?
Genomic testing is a type of advanced diagnostic test, referred to as molecular diagnostics. These tests look at the behaviour of the genes within your specific tumour tissue. The behaviour of these genes determines how likely the cancer is to grow and spread. It can also provide consultants with an insight into which treatment options may be most effective for your individual tumour.
Our dedicated molecular diagnostic lab, The Sarah Cannon Molecular Diagnostics Lab, part of HCA UK, can provide the expertise and in-house tests to provide genomic insights for your individual cancer. These genomic insights may identify additional treatment options such as immunotherapy or access to new and emerging therapies through clinical trials.
What are the benefits of genomic testing?
A better understanding of the genetics driving your individual tumour and how likely it is to respond to certain therapies.
Helps us to identify personalised medicine treatment options – designed to target your individual tumour.
Find out if there are any alternative treatments that may be more effective at targeting your tumour, such as immunotherapies, targeted therapies or new and emerging therapies through clinical trials.
If your consultant recommends genomic testing, they will discuss this with you in detail so that you can make an informed decision as part of your personalised treatment plan.
Access to clinical trials
A clinical trial is a research study that compares how effective different treatments are. There are different types of clinical trials, but they are all highly regulated and closely monitored to ensure safety. Access to clinical trials means you may be one of the first people to benefit from a new treatment.
It’s important to remember that not all clinical trials result in new, better treatments as they are still in development. If your consultant thinks you may benefit from a clinical trial, they will discuss this with you in detail so that you can make an informed decision about taking part.
About clinical trials at HCA UK
At HCA Healthcare UK we are committed to advancing medicine and are proud to be the only private healthcare provider in the UK to operate a dedicated clinical trials facility, The Sarah Cannon Research Institute (SCRI).
Having this dedicated clinical trials facility, which works in partnership with our molecular diagnostic lab, means that we are able to provide the kindest and most effective treatment for your cancer and access to new and emerging therapies at the earliest opportunity.
Finding more options through clinical trials
Since 2012, Sezgin Hick has been receiving treatment following a late-stage ovarian cancer diagnosis. After surgery and different combinations of chemotherapy, her cancer was no longer responding to standard therapies. It was at this point Sezgin’s consultant recommended a Phase 1 clinical trial at the Sarah Cannon Research Institute (SCRI), part of HCA Healthcare UK. Read more about Sezgin and her experience of being on a clinical trial.
A new era in ovarian cancer treatment
The past twenty years have seen many advancements in the way we treat ovarian cancer, transforming outcomes for patients. Progress in genomic testing, immunotherapy, targeted therapies and access to clinical trials have been the driving force of this innovation.
Dr Jonathan Krell, Consultant Oncologist from The LOC, part of HCA Healthcare UK, shares his insights into these latest advancements and the developments that are driving the future.
Getting a second opinion
If you have been diagnosed with cancer, whether or not you have started treatment, a second opinion can give you reassurance and peace of mind.
Our second opinion service is led by expert consultants. They will provide a comprehensive review of your current and past medical history, to identify the best treatment options for you. This review may identify new treatment options or simply confirm you are already receiving the best treatment. Either way it can help you make an informed decision about what is best for you.
We offer a second opinion service in London, Birmingham and Manchester, covering a wide range of specialities.